Breaking News Instant updates and real-time market news.

AVRO

Avrobio

$19.08

2.66 (16.20%)

04:25
07/17/19
07/17
04:25
07/17/19
04:25

Avrobio 6.5M share Secondary priced at $18.50

The deal size was increased to $120.25M in common stock from $100M in common stock. Morgan Stanley and Cowen acted as joint book running managers for the offering.

  • 09

    Sep

  • 17

    Jul

AVRO Avrobio
$19.08

2.66 (16.20%)

01/17/19
LEER
01/17/19
NO CHANGE
Target $19
LEER
Market Perform
Avrobio price target lowered to $19 from $27 at Leerink
Leerink analyst Mani Foroohar lowered his price target for Avrobio to $19 from $27, while reiterating a Market Perform rating on the shares. While the analyst is positive on recent additions to senior management, he is more conservative on the market opportunity for Fabry gene therapy given the need for higher-intensity preconditioning regimens than the company has used previously, and believes that the potential adoption of value-based annuity pricing models by the industry could pose further risk to Avrobio's bottom line.
04/05/19
JANY
04/05/19
INITIATION
JANY
Buy
Avrobio initiated with a Buy at Janney Montgomery Scott
06/26/19
MZHO
06/26/19
INITIATION
Target $28
MZHO
Buy
Avrobio initiated with a Buy at Mizuho
Mizuho analyst Difei Yang initiated Avrobio with a Buy and $28 price target.
06/27/19
MZHO
06/27/19
INITIATION
Target $28
MZHO
Buy
Mizuho starts Avrobio with Buy rating, $28 price target
Mizuho analyst Difei Yang last night initiated coverage of Avrobio with a Buy rating and $28 price target. Avrobio is a gene therapy company using a proprietary ex-vivo lentiviral vector platform to address unmet needs in lysosomal storage diseases, a $4B total addressable market, Yang tells investors in a research note. The analyst believes available clinical data in Fabry disease has shown "encouraging" results.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.